Loading...
Header Logo
Keywords
Last Name
Institution

John L Stock MD

TitleProfessor
InstitutionUniversity of Massachusetts Medical School
DepartmentMedicine
Address3521 Northwest Clubside Circlt
Boca Raton FL 33496
Phone508-340-0344
vCardDownload vCard
    Other Positions
    InstitutionUMMS - School of Medicine
    DepartmentMedicine
    DivisionEndocrinology & Metabolism


    Collapse Biography 
    Collapse education and training
    Cornell University, Ithaca, NY, United StatesABChemistry
    Harvard Medical School, Boston, MA, United StatesMD

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013; 13:15. PMID: 23521803.
      View in: PubMed
    2. Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012 Aug; 23(8):2141-50. PMID: 22159672.
      View in: PubMed
    3. Cummings SR, McClung M, Reginster JY, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011 Feb; 26(2):397-404. PMID: 20658564.
      View in: PubMed
    4. Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR. Effect of Raloxifene on all-cause mortality. Am J Med. 2010 May; 123(5):469.e1-7. PMID: 20399327.
      View in: PubMed
    5. Stock JL, Mershon JL, Schoenfeld MJ. Review of comparative effectiveness of treatments to prevent fractures. Ann Intern Med. 2008 Jun 3; 148(11):885; author reply 887. PMID: 18519941.
      View in: PubMed
    6. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA. Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008 Jan; 23(1):112-20. PMID: 17892376.
      View in: PubMed
    7. Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr; 40(4):843-51. PMID: 17182297.
      View in: PubMed
    8. Meadows ES, Stock J, Johnston JA. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies. Med Decis Making. 2006 Nov-Dec; 26(6):633-5; author reply 636-7. PMID: 17099202.
      View in: PubMed
    9. Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin. 2005 Dec; 21(12):1955-9. PMID: 16368046.
      View in: PubMed
    10. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005 Sep; 20(9):1514-24. PMID: 16059623.
      View in: PubMed
    11. Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. J Clin Densitom. 2005; 8(3):273-7. PMID: 16055956.
      View in: PubMed
    12. Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. J Fam Pract. 2004 Oct; 53(10):789-96. PMID: 15469774.
      View in: PubMed
    13. Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc. 2004 Sep; 52(9):1543-8. PMID: 15341559.
      View in: PubMed
    14. Lufkin EG, Sarkar S, Kulkarni PM, Ciaccia AV, Siddhanti S, Stock J, Plouffe L. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin. 2004 Mar; 20(3):351-7. PMID: 15025844.
      View in: PubMed
    15. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003 Oct; 33(4):522-32. PMID: 14555255.
      View in: PubMed
    16. Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002 Feb; 23(1):16-37. PMID: 11844743.
      View in: PubMed
    17. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002 Jan; 17(1):1-10. PMID: 11771654.
      View in: PubMed
    18. El-Hajj Fuleihan G, Stock JL, McClung MR, Saifi G. A national random survey of bone mineral density reporting in the United States. J Clin Densitom. 2002; 5(1):3-9. PMID: 11940723.
      View in: PubMed
    19. Stock JL, Brown RS, Baron J, Coderre JA, Mancilla E, De Luca F, Ray K, Mericq MV. Autosomal dominant hypoparathyroidism associated with short stature and premature osteoarthritis. J Clin Endocrinol Metab. 1999 Sep; 84(9):3036-40. PMID: 10487661.
      View in: PubMed
    20. Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, Rosen CJ, Kessenich CR, Stock JL, Overdorf J, Miller PD, Erickson AL, McCLung MR, McClung BL, Griffith LE, Ioannidis G. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int. 1999; 10(3):207-13. PMID: 10525712.
      View in: PubMed
    21. Stock JL, Coderre JA, Overdorf JH, Fitzpatrick LA, Shapiro JR. Calvarial doughnut lesions associated with high-turnover osteoporosis presenting in childhood. J Clin Densitom. 1999; 2(1):45-53. PMID: 23547313.
      View in: PubMed
    22. Stock JL, Coderre JA, DeVito WJ, Baker S. Effects of human lymphocyte-conditioned medium on MG-63 human osteosarcoma cell function. Cytokine. 1998 Aug; 10(8):603-12. PMID: 9722933.
      View in: PubMed
    23. Stock JL, Waud CE, Coderre JA, Overdorf JH, Janikas JS, Heiniluoma KM, Morris MA. Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis. A randomized trial. Ann Intern Med. 1998 Jun 15; 128(12 Pt 1):996-9. PMID: 9625686.
      View in: PubMed
    24. Stock JL, Bell NH, Chesnut CH, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 1997 Oct; 103(4):291-7. PMID: 9382121.
      View in: PubMed
    25. Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, Baumann G, Hintz RL, Hartman ML, Seizinger BR, Larsson C, Aronin N. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab. 1997 Feb; 82(2):486-92. PMID: 9024241.
      View in: PubMed
    26. Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995 Aug; 99(2):144-52. PMID: 7625419.
      View in: PubMed
    27. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994 Oct; 14(10):1586-93. PMID: 7522547.
      View in: PubMed
    28. Shewmon DA, Stock JL, Abusamra LC, Kristan MA, Baker S, Heiniluoma KM. Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism. 1994 May; 43(5):531-2. PMID: 8177039.
      View in: PubMed
    29. Zayed A, Stock JL, Liepman MK, Wollin M, Longcope C. Feminization as a result of both peripheral conversion of androgens and direct estrogen production from an adrenocortical carcinoma. J Endocrinol Invest. 1994 Apr; 17(4):275-8. PMID: 7930380.
      View in: PubMed
    30. Stock JL, Coderre JA, Burke EM, Danner DB, Chipman SD, Shapiro JR. Identification of estrogen receptor mRNA and the estrogen modulation of parathyroid hormone-stimulated cyclic AMP accumulation in opossum kidney cells. J Cell Physiol. 1992 Mar; 150(3):517-25. PMID: 1311330.
      View in: PubMed
    31. Rockwell JC, Sorensen AM, Baker S, Leahey D, Stock JL, Michaels J, Baran DT. Weight training decreases vertebral bone density in premenopausal women: a prospective study. J Clin Endocrinol Metab. 1990 Oct; 71(4):988-93. PMID: 2401722.
      View in: PubMed
    32. Stock JL, Coderre JA, McDonald B, Rosenwasser LJ. Effects of estrogen in vivo and in vitro on spontaneous interleukin-1 release by monocytes from postmenopausal women. J Clin Endocrinol Metab. 1989 Feb; 68(2):364-8. PMID: 2783934.
      View in: PubMed
    33. Stock JL, Coderre JA, Posillico JT. Effects of estrogen on mineral metabolism in postmenopausal women as evaluated by multiple assays measuring parathyrin bioactivity. Clin Chem. 1989 Jan; 35(1):18-22. PMID: 2535973.
      View in: PubMed
    34. Popoff SN, Coderre JA, Marks SC, Stock JL. Calcitonin inhibits accumulation of cyclic AMP in stimulated peritoneal macrophages from normal rats but not from osteopetrotic (incisors-absent) littermates. Life Sci. 1989; 45(21):2007-13. PMID: 2557510.
      View in: PubMed
    35. Stock JL, Coderre JA. Pertussis toxin blocks the inhibitory effects of calcitonin on cyclic AMP accumulation in stimulated cultured human monocytes. J Leukoc Biol. 1987 Nov; 42(5):504-9. PMID: 2824646.
      View in: PubMed
    36. Schiller JH, Rasmussen P, Benson AB, Witte RS, Bockman RS, Harvey HA, Siris ES, Citrin DL, Greco FA, Stock JL. Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med. 1987 May; 147(5):963-6. PMID: 3107487.
      View in: PubMed
    37. Stock JL, Coderre JA, Mallette LE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 1985 Oct; 61(4):595-600. PMID: 2993339.
      View in: PubMed
    38. Stock JL, Coderre JA. Calcitonin enhances production of prostaglandins by stimulated human monocytes. Prostaglandins. 1984 May; 27(5):771-9. PMID: 6087420.
      View in: PubMed
    39. Manning GS, Stevens KA, Stock JL. Multiple endocrine neoplasia, type I. Association with marfanoid habitus, optic atrophy, and other abnormalities. Arch Intern Med. 1983 Dec; 143(12):2315-6. PMID: 6139988.
      View in: PubMed
    40. Attie MF, Gill JR, Stock JL, Spiegel AM, Downs RW, Levine MA, Marx SJ. Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest. 1983 Aug; 72(2):667-76. PMID: 6874959.
      View in: PubMed
    41. Stock JL, Coderre JA. Calcitonin and parathyroid hormone inhibit accumulation of cyclic AMP in stimulated human mononuclear cells. Biochem Biophys Res Commun. 1982 Dec 15; 109(3):935-42. PMID: 6186255.
      View in: PubMed
    42. Stock JL, Coderre JA, Levine PH. Effects of calcium-regulating hormones and drugs on human monocyte chemiluminescence. J Clin Endocrinol Metab. 1982 Nov; 55(5):956-60. PMID: 6214564.
      View in: PubMed
    43. Marx SJ, Stock JL, Attie MF, Downs RW, Gardner DG, Brown EM, Spiegel AM, Doppman JL, Brennan MF. Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration. Ann Intern Med. 1980 Mar; 92(3):351-6. PMID: 7356229.
      View in: PubMed
    44. Marx SJ, Spiegel AM, Sharp ME, Brown EM, Gardner DG, Downs RW, Attie MF, Stock JL. Adenosine 3',5'-monophosphate response to parathyroid hormone: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. J Clin Endocrinol Metab. 1980 Mar; 50(3):546-8. PMID: 6244324.
      View in: PubMed
    45. Marx SJ, Spiegel AM, Brown EM, Downs RW, Attie MF, Stock JL, Levine MA, Aurbach GD. Urinary cyclic 3',5'-adenosine monophosphate (cAMP): an index of the action of parathyroid hormone on the kidney. Prog Biochem Pharmacol. 1980; 17:182-9. PMID: 6259655.
      View in: PubMed
    For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
    Stock's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _